zip >>> 94404
sector >>> Healthcare
fullTimeEmployees >>> 11800
longBusinessSummary >>> Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
city >>> Foster City
phone >>> 650-574-3000
state >>> CA
country >>> United States
companyOfficers >>> []
website >>> http://www.gilead.com
maxAge >>> 1
address1 >>> 333 Lakeside Drive
fax >>> 650-578-9264
industry >>> Drug Manufacturers—General
previousClose >>> 62.25
regularMarketOpen >>> 62.1
twoHundredDayAverage >>> 73.2336
trailingAnnualDividendYield >>> 0.042088352
payoutRatio >>> None
volume24Hr >>> None
regularMarketDayHigh >>> 62.505
navPrice >>> None
averageDailyVolume10Day >>> 9032057
totalAssets >>> None
regularMarketPreviousClose >>> 62.25
fiftyDayAverage >>> 65.87941
trailingAnnualDividendRate >>> 2.62
open >>> 62.1
toCurrency >>> None
averageVolume10days >>> 9032057
expireDate >>> None
yield >>> None
algorithm >>> None
dividendRate >>> 2.72
exDividendDate >>> 1600041600
beta >>> 0.57748
circulatingSupply >>> None
startDate >>> None
regularMarketDayLow >>> 61.765
priceHint >>> 2
currency >>> USD
regularMarketVolume >>> 6779205
lastMarket >>> None
maxSupply >>> None
openInterest >>> None
marketCap >>> 78044069888
volumeAllCurrencies >>> None
strikePrice >>> None
averageVolume >>> 8698217
priceToSalesTrailing12Months >>> 3.519621
dayLow >>> 61.765
ask >>> 62.28
ytdReturn >>> None
askSize >>> 800
volume >>> 6779205
fiftyTwoWeekHigh >>> 85.97
forwardPE >>> 8.918338
fromCurrency >>> None
fiveYearAvgDividendYield >>> 2.83
fiftyTwoWeekLow >>> 60.89
bid >>> 62.07
tradeable >>> False
dividendYield >>> 0.0437
bidSize >>> 900
dayHigh >>> 62.505
exchange >>> NMS
shortName >>> Gilead Sciences, Inc.
longName >>> Gilead Sciences, Inc.
exchangeTimezoneName >>> America/New_York
exchangeTimezoneShortName >>> EDT
isEsgPopulated >>> False
gmtOffSetMilliseconds >>> -14400000
quoteType >>> EQUITY
symbol >>> GILD
messageBoardId >>> finmb_29002
market >>> us_market
annualHoldingsTurnover >>> None
enterpriseToRevenue >>> 3.738
beta3Year >>> None
profitMargins >>> -0.01159
enterpriseToEbitda >>> 14.899
52WeekChange >>> -0.017829001
morningStarRiskRating >>> None
forwardEps >>> 6.98
revenueQuarterlyGrowth >>> None
sharesOutstanding >>> 1253720064
fundInceptionDate >>> None
annualReportExpenseRatio >>> None
bookValue >>> 14.376
sharesShort >>> 16172946
sharesPercentSharesOut >>> 0.0128999995
fundFamily >>> None
lastFiscalYearEnd >>> 1577750400
heldPercentInstitutions >>> 0.80768996
netIncomeToCommon >>> -257000000
trailingEps >>> -0.204
lastDividendValue >>> None
SandP52WeekChange >>> 0.108078
priceToBook >>> 4.3301334
heldPercentInsiders >>> 0.0040599997
nextFiscalYearEnd >>> 1640908800
mostRecentQuarter >>> 1593475200
shortRatio >>> 1.67
sharesShortPreviousMonthDate >>> 1596153600
floatShares >>> 1252144677
enterpriseValue >>> 82896338944
threeYearAverageReturn >>> None
lastSplitDate >>> 1359331200
lastSplitFactor >>> 2:1
legalType >>> None
morningStarOverallRating >>> None
earningsQuarterlyGrowth >>> None
dateShortInterest >>> 1598832000
pegRatio >>> 37.04
lastCapGain >>> None
shortPercentOfFloat >>> 0.0128999995
sharesShortPriorMonth >>> 21332170
category >>> None
fiveYearAverageReturn >>> None
regularMarketPrice >>> 62.1
logo_url >>> https://logo.clearbit.com/gilead.com
